...we conducted a phase II multicenter study evaluated the efficacy and safety of bortezomib plus pegylated liposomal doxorubicin (PLD) in patients with BRCA wild-type platinum-resistant recurrent ovarian cancer (NCT03509246)....The combination of bortezomib and PLD was well tolerated....The overall confirmed ORR was 8.7% (2/23); partial response was observed in two patients. Disease control was achieved in 69.6% (16/23) patients (Table IV). Tumor shrinkage was noted in 9 (39.1%) of 23 patients who had at least one post-baseline efficacy assessment (Figure 2). The mean best percentage change of the target lesion size from the baseline was –0.6% (SD 19.1). The median duration of response was 10.5 months...the median PFS was 2.9 months, and median OS was 19.0 months (Figure 3).